“Advances in Antibody-Drug Conjugate (ADC) Technology”
Advances in antibody-drug conjugate (ADC) technology are driving growth in the global ADC market by enhancing both treatment effectiveness and safety in cancer care. Key innovations trends include improved linkers for stable, precise drug delivery that targets cancer cells while sparing healthy tissue. Next-generation ADCs with optimized payloads and biomarker-driven patient selection ensure that therapies reach those who will benefit most, minimizing side effects. In addition, improved manufacturing processes are lowering production costs, increasing access, and encouraging greater investment in ADC development, all contributing to a robust pipeline and expanding market interest.
